Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers

Kasper Iversen, Jonas Henrik Kristensen, Rasmus Bo Hasselbalch, Mia Pries-Heje, Pernille Brok Nielsen, Andreas Dehlbæk Knudsen, Kamille Fogh, Jakob Boesgaard Norsk, Ove Andersen, Thea Køhler Fischer, Claus Antonio Juul Jensen, Christian Torp-Pedersen, Jørgen Rungby, Sisse Bolm Ditlev, Ida Hageman, Rasmus Møgelvang, Mikkel Gybel-Brask, Ram B Dessau, Erik Sørensen, Lene Harritshøj, Fredrik Folke, Curt Sten, Maria Elizabeth Engel Møller, Thomas Benfield, Henrik Ullum, Charlotte Sværke Jørgensen, Christian Erikstrup, Sisse R Ostrowski, Susanne Dam Nielsen, Henning Bundgaard, Kasper Iversen, Jonas Henrik Kristensen, Rasmus Bo Hasselbalch, Mia Pries-Heje, Pernille Brok Nielsen, Andreas Dehlbæk Knudsen, Kamille Fogh, Jakob Boesgaard Norsk, Ove Andersen, Thea Køhler Fischer, Claus Antonio Juul Jensen, Christian Torp-Pedersen, Jørgen Rungby, Sisse Bolm Ditlev, Ida Hageman, Rasmus Møgelvang, Mikkel Gybel-Brask, Ram B Dessau, Erik Sørensen, Lene Harritshøj, Fredrik Folke, Curt Sten, Maria Elizabeth Engel Møller, Thomas Benfield, Henrik Ullum, Charlotte Sværke Jørgensen, Christian Erikstrup, Sisse R Ostrowski, Susanne Dam Nielsen, Henning Bundgaard

Abstract

Objectives: Antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are a key factor in protecting against coronavirus disease 2019 (COVID-19). We examined longitudinal changes in seroprevalence in healthcare workers (HCWs) in Copenhagen and the protective effect of antibodies against SARS-CoV-2.

Methods: In this prospective study, screening for antibodies against SARS-CoV-2 (ELISA) was offered to HCWs three times over 6 months. HCW characteristics were obtained by questionnaires. The study was registered at ClinicalTrials.gov, NCT04346186.

Results: From April to October 2020 we screened 44 698 HCWs, of whom 2811 were seropositive at least once. The seroprevalence increased from 4.0% (1501/37 452) to 7.4% (2022/27 457) during the period (p < 0.001) and was significantly higher than in non-HCWs. Frontline HCWs had a significantly increased risk of seropositivity compared to non-frontline HCWs, with risk ratios (RRs) at the three rounds of 1.49 (95%CI 1.34-1.65, p < 0.001), 1.52 (1.39-1.68, p < 0.001) and 1.50 (1.38-1.64, p < 0.001). The seroprevalence was 1.42- to 2.25-fold higher (p < 0.001) in HCWs from dedicated COVID-19 wards than in other frontline HCWs. Seropositive HCWs had an RR of 0.35 (0.15-0.85, p 0.012) of reinfection during the following 6 months, and 2115 out of 2248 (95%) of those who were seropositive during rounds one or two remained seropositive after 4-6 months. The 133 of 2248 participants (5.0%) who seroreverted were slightly older and reported fewer symptoms than other seropositive participants.

Conclusions: HCWs remained at increased risk of infection with SARS-CoV-2 during the 6-month period. Seropositivity against SARS-CoV-2 persisted for at least 6 months in the vast majority of HCWs and was associated with a significantly lower risk of reinfection.

Keywords: COVID; Healthcare workers; Immune response; SARS-CoV-2; Seroprevalence.

Copyright © 2021. Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Flow of participants in the study: healthcare workers (HCWs) participating in the study during the period from April to October 2020.
Fig. 2
Fig. 2
Risk of seropositivity according to occupational exposure: seroprevalence among healthcare workers (HCWs) at each round stratified by HCWs working in dedicated coronavirus disease 2019 (COVID-19) wards, HCWs not on COVID-19 wards but working frontline, and remaining HCWs.
Fig. 3
Fig. 3
Seroprevalence stratified by medical specialty for doctors, nurses and assistant nurses. The figure shows seroprevalence among doctors, nurses and assistant nurses stratified by medical specialty. Some specialties are more involved in the treatment of patients with coronavirus disease 2019 (COVID-19) than others, for example a high seroprevalence is noted for respiratory medicine, infectious diseases and emergency medicine. Elderly and/or immunosuppressed patients may shed more virus, which may explain why geriatrics and haematology rank high. Also, in geriatrics, healthcare workers (HCWs) visit patients in their homes where transmission may be higher than in hospitals. Surprisingly, the seroprevalence in intensive care is low compared to other specialties.
Fig. 4
Fig. 4
Signal/cutoff ratio (S/CO ratio) for participants who were seropositive in round one and participated in all three rounds (n = 817). (a) S/CO ratio in all three rounds (n = 745). (b) Seroreverters in round two (n = 26) (positive in round one and negative in rounds two and three). (c) Seroreverters in round three (n = 21) (positive in round one and negative in rounds two and three). (d) Possible reinfections (n = 25) (positive in round one, negative in round two and positive in round three). The dotted line signifies 1.1, above which was considered positive.

References

    1. WHO Coronavirus (COVID-19) Dashboard . 2021. WHO Coronavirus Disease (COVID-19) Dashboard [Internet] [cited 24th Mar] Available from:
    1. Jeyanathan M., Afkhami S., Smaill F., Miller M.S., Lichty B.D., Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615–632.
    1. Lumley S.F., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384:533–540.
    1. Long Q.-X., Liu B.-Z., Deng H.-J., Wu G.-C., Deng K., Chen Y.-K., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–848.
    1. Wajnberg A., Mansour M., Leven E., Bouvier N.M., Patel G., Firpo-Betancourt A., et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe. 2020;1:e283–e289.
    1. Post N., Eddy D., Huntley C., van Schalkwyk M.C.I., Shrotri M., Leeman D., et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2020;15:e0244126.
    1. Tillett R.L., Sevinsky J.R., Hartley P.D., Kerwin H., Crawford N., Gorzalski A., et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21:52–58.
    1. Van Elslande J., Vermeersch P., Vandervoort K., Wawina-Bokalanga T., Vanmechelen B., Wollants E., et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2021;73:354–356.
    1. Prado-Vivar B., Becerra-Wong M., Guadalupe J.J., Marquez S., Gutierrez B., Rojas-Silva P., et al. COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America. SSRN Electron J [Internet] 2020 [cited 2021 Feb 5]
    1. To K.K., Hung I.F., Ip J.D., Chu A.W., Chan W.M., Tam A.R., et al. Coronavirus Disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 Strain confirmed by whole genome sequencing. Clin Infect Dis. 2021;73:e2946–e2951.
    1. Gupta V., Bhoyar R.C., Jain A., Srivastava S., Upadhayay R., Imran M., et al. Asymptomatic reinfection in 2 healthcare workers from India with genetically distinct severe acute respiratory syndrome coronavirus 2. Clin Infect Dis. 2021;73:e2823–e2825.
    1. Mumoli N., Vitale J., Mazzone A. Clinical immunity in discharged medical patients with COVID-19. Int J Infect Dis. 2020;99:229–230.
    1. Gousseff M., Penot P., Gallay L., Batisse D., Benech N., Bouiller K., et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infect. 2020;81:816–846.
    1. Reinfection with SARS-CoV-2: considerations for public health response [Internet] 2020. Available from:
    1. Long Q.X., Tang X.J., Shi Q.L., Li Q., Deng H.J., Yuan J., et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–1204.
    1. Iversen K., Bundgaard H., Hasselbalch R.B., Kristensen J.H., Nielsen P.B., Pries-Heje M., et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis. 2020;20:1401–1408.
    1. Harris P.A., Taylor R., Minor B.L., Elliott V., Fernandez M., O’Neal L., et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
    1. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381.
    1. Erikstrup C., Hother C.E., Pedersen O.B.V., Mølbak K., Skov R.L., Holm D.K., et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2020;72:249–253.
    1. Hansen C.H., Michlmayr D., Gubbels S.M., Mølbak K., Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397:1204–1212.
    1. Harvey R.A., Rassen J.A., Kabelac C.A., Turenne W., Leonard S., Klesh R., et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181:672–679.
    1. Public Health England . 2020. Weekly national Influenza and COVID-19 surveillance report.
    1. Wajnberg A., Amanat F., Firpo A., Altman D.R., Bailey M.J., Mansour M., et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–1230.
    1. Harvey R.A., Rassen J.A., Kabelac C.A., Turenne W., Leonard S., Klesh R., et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. medRxiv. 2020 2020.12.18.2024833. Preprint.
    1. Choe P.G., Kang C.K., Suh H.J., Jung J., Song K.H., Bang J.H., et al. Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection. Emerg Infect Dis. 2021;27:327–329.
    1. Madsen J.R., Nielsen J.P.S., Fogh K., Hansen C.B., Nielsen P.B., Lange T., et al. Anti-SARS-CoV-2 seropositivity among medical students in Copenhagen. Open Forum Infect Dis. 2021;8:ofab273.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner